CSM recommendations
Prolonged use of cyproterone may produce dose-related hepatotoxicity. Effects include:
- hepatitis
- cholestatic jaundice
- hepatic failure
- death
The Committee on the Safety of Medicine recommend that:
- long-term daily doses of 300 mg be restricted to:
- short courses to cover the effects of LHRH agonists or following orchidectomy
- patients who fail to respond to, or cannot tolerate, alternative treatments
- liver function tests are conducted before treatment and whenever hepatic impairment is suspected
- cyproterone is withheld once evidence of hepatotoxicity develops
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.